glp-1 kidney protection receptor agonists are increasingly used to treat type 2 diabetes and #obesity, and trials have shown reductions in cardiovascular risk and slowing of failure. Adverse events are mostly gastrointestinal. Read Glucagon-like peptide-1 receptor agonists in

Following protein clusters were manually identified to be involved in GSH synthesis and metabolism viz

AbbVies tavapadon targets motor symptoms of Parkinsons with a more specific mechanism than existing drugs, potentially meaning more benefits with fewer side effects

While there are no clinical studies suggesting it is harmful to nursing infants, you should always consult your pediatrician before starting a supplement to ensure it is appropriate for your specific situation

Some researchers have asked whether combining cagrilintide (the amylin component of CagriSema) with tirzepatide (the GIP/GLP-1 dual agonist) could produce even greater results

A 2019 meta-analysis noted mixed outcomes in autoimmune thyroid conditions, with some studies showing reduced TPO antibodies and improved TSH control, while others showed minimal clinical benefit

Diab/Metab Res Rev 24(1):5963 Davis EC et al (2022) Gut microbiome and breast-feeding: Implications for early immune development